Yesterday Bob Nightengale reported that Major League Baseball was targeting Ryan Braun in the Biogenesis investigation, to the point where it was willing to grant other players immunity — and sacrifice most of its drug enforcement principles — in order to take Braun down.
Later in the day, however, MLB’s Rob Manfred denied that. From Tom Haudricourt of the Milwaukee Journel-Sentinel:
Major League Baseball executive vice president Rob Manfred denied that MLB has targeted Milwaukee Brewers leftfielder Ryan Braun specifically in its investigation of the Biogenesis clinic in Miami, as suggested by a USA Today article.
“Everyone whose name has surfaced surrounding the Miami New Times story and Biogenesis is being investigated with equal vigor,” Manfred said in a statement to the Journal Sentinel.
Which would be great if now other reporters, also well-connected ones like Nightengale, weren’t continuing to hear otherwise. Here’s Yahoo!’s Jeff Passan from last night:
Major League Baseball is honing in on Alex Rodriguez and Ryan Braun as two main targets for potential discipline as it prepares to interview players about the Biogenesis clinic … Multiple sources said the league has discussed offers of immunity to major league players, though none has been officially offered … The league has interviewed players not on 40-man rosters, and one such player told Yahoo! Sports he was offered immunity in exchange for information about Biogenesis. [emphasis added]
Passan’s report backs Nightengale’s account way more than it backs a situation in which MLB’s claim that everyone is being investigated with “equal vigor.”
As I said yesterday, baseball can do whatever it wants. But if it is granting immunity to some players it is abandoning its zero tolerance policies and turning the drug enforcement program into a totally different animal than they have long claimed it to be.
According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.
A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.
Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.
Espinosa will reach free agency after the 2017 season.
The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.
The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.
Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.
Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.